Scarica l'app Stockscreener
22.70
0.39%
-0.09
Dopo l'orario di chiusura:
22.70
Precedente Chiudi:
$22.79
Aprire:
$22.4
Volume 24 ore:
749.19K
Relative Volume:
0.86
Capitalizzazione di mercato:
$919.12M
Reddito:
$726.41M
Utile/perdita netta:
$7.03M
Rapporto P/E:
144.49
EPS:
0.1571
Flusso di cassa netto:
$136.66M
1 W Prestazione:
-2.62%
1M Prestazione:
+6.67%
6M Prestazione:
-7.65%
1 anno Prestazione:
-8.80%
Intervallo 1D:
$22.18
$22.93
Intervallo di 1 settimana:
$22.18
$23.61
Portata 52W:
$18.80
$27.98
Pacira Biosciences Inc Stock (PCRX) Company Profile
Nome
Pacira Biosciences Inc
Settore
Telefono
650-242-8052
Indirizzo
2000 SIERRA POINT PARKWAY, BRISBANE, NJ
Compare PCRX vs TAK, ZTS, HLN, TEVA, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PCRX
Pacira Biosciences Inc
|
22.70 | 919.12M | 726.41M | 7.03M | 136.66M | 0.1571 |
TAK
Takeda Pharmaceutical Co Adr
|
18.74 | 59.20B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
117.94 | 49.79B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.93 | 44.27B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.08 | 35.03B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
564.81 | 24.75B | 3.18B | 1.33B | 1.04B | 27.90 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-09 | Iniziato | Barclays | Equal Weight |
| 2025-11-17 | Iniziato | H.C. Wainwright | Buy |
| 2025-07-25 | Aggiornamento | Truist | Hold → Buy |
| 2025-01-30 | Aggiornamento | Truist | Sell → Hold |
| 2024-08-13 | Downgrade | Truist | Buy → Sell |
| 2024-08-12 | Downgrade | JP Morgan | Overweight → Underweight |
| 2024-08-12 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-08-12 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-08-12 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2024-07-03 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-03-07 | Ripresa | JP Morgan | Overweight |
| 2023-12-20 | Iniziato | Raymond James | Outperform |
| 2023-08-03 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-01-31 | Ripresa | Wedbush | Outperform |
| 2022-10-21 | Ripresa | Jefferies | Buy |
| 2022-01-03 | Ripresa | JP Morgan | Overweight |
| 2021-07-26 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-04-21 | Ripresa | JP Morgan | Neutral |
| 2021-04-09 | Iniziato | Berenberg | Buy |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2021-02-11 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2021-01-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-09-21 | Aggiornamento | Northland Capital | Market Perform → Outperform |
| 2020-07-06 | Reiterato | Needham | Buy |
| 2020-05-27 | Iniziato | Guggenheim | Neutral |
| 2020-04-07 | Iniziato | Northland Capital | Outperform |
| 2020-03-20 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2020-02-24 | Reiterato | H.C. Wainwright | Buy |
| 2020-01-24 | Iniziato | SunTrust | Buy |
| 2020-01-23 | Iniziato | SunTrust | Buy |
| 2019-11-06 | Iniziato | BTIG Research | Buy |
| 2019-06-11 | Iniziato | Barclays | Overweight |
| 2019-05-06 | Aggiornamento | Mizuho | Underperform → Neutral |
| 2019-05-02 | Aggiornamento | Stifel | Sell → Hold |
| 2019-02-01 | Downgrade | Mizuho | Neutral → Underperform |
| 2018-08-06 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2018-04-09 | Reiterato | H.C. Wainwright | Buy |
| 2018-03-21 | Reiterato | Mizuho | Neutral |
| 2018-02-16 | Downgrade | Needham | Buy → Hold |
| 2018-01-19 | Iniziato | Seaport Global Securities | Buy |
| 2018-01-04 | Reiterato | Canaccord Genuity | Buy |
| 2018-01-03 | Iniziato | Leerink Partners | Mkt Perform |
Mostra tutto
Pacira Biosciences Inc Borsa (PCRX) Ultime notizie
2026-04-05 | Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRX) Stockholders to Inquire about Securities Investigation | NDAQ:PCRX | Press Release - Stockhouse
PCRX Technical Analysis & Stock Price Forecast - Intellectia AI
Pacira (PCRX) BioSciences well-positioned with genicular outcomes registry evidence - MSN
PCRX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
2026-04-02 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Investors to Learn More About the Investigation | NDAQ:PCRX | Press Release - Stockhouse
Pacira BioSciences, Inc. (PCRX) Stock Forecasts - finance.yahoo.com
Analysts Set Expectations for PCRX Q1 Earnings - MarketBeat
(PCRX) Risk Channels and Responsive Allocation - Stock Traders Daily
2026-03-31 | Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:PCRX | Press Release - Stockhouse
Pacira (PCRX) BioSciences Well-Positioned With Genicular Outcomes Registry Evidence - Insider Monkey
Hennion & Walsh Asset Management Inc. Acquires 87,210 Shares of Pacira BioSciences, Inc. $PCRX - MarketBeat
Pacira BioSciences to Present Real-World Data on EXPAREL Showing Reduced Cost of Care at Orthopaedic Research Society 2026 Annual Meeting - Bitget
Pacira BioSciences to Present Real-World Data on EXPAREL® Showing Reduced Cost of Care at Orthopaedic Research Society 2026 Annual Meeting - Ortho Spine News
Study data linked EXPAREL to lower knee and spine surgery costs - Stock Titan
2026-03-29 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRX) And Encourages Investors to Connect | NDAQ:PCRX | Press Release - Stockhouse
Pacira BioSciences, Inc. $PCRX Shares Purchased by Assenagon Asset Management S.A. - MarketBeat
Bull Run: Is Pacira BioSciences Inc impacted by rising ratesQuarterly Profit Report & Expert Curated Trade Ideas - baoquankhu1.vn
Vanguard amends Schedule 13G/A after internal realignment (PCRX) - stocktitan.net
Absci, DigitalOcean And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Sahm
2026-03-26 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Stockholders to Learn More About the Investigation | NDAQ:PCRX | Press Release - Stockhouse
Pacira BioSciences (NASDAQ:PCRX) Price Target Cut to $25.00 by Analysts at Barclays - MarketBeat
PCRX: Barclays Lowers Price Target to $25, Maintains Equal-Weigh - GuruFocus
2026-03-24 | Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRX) Investors to Inquire about Securities Investigation | NDAQ:PCRX | Press Release - Stockhouse
Pacira faces board fight as activist investor criticizes CEO pay, missed earnings - MSN
(PCRX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Froimson Mark sells Pacira BioSciences (PCRX) shares for $10905 By Investing.com - Investing.com India
Insider Sell: Jonathan Slonin Sells Shares of Pacira BioSciences Inc (PCRX) - GuruFocus
Pacira BioSciences’ chief medical officer sells $74k in stock By Investing.com - Investing.com Australia
Insider Selling: Pacira BioSciences (NASDAQ:PCRX) Insider Sells 3,261 Shares of Stock - MarketBeat
Froimson Mark sells Pacira BioSciences (PCRX) shares for $10905 - Investing.com UK
Pacira BioSciences (PCRX) director receives 6,163 restricted stock units in equity grant - Stock Titan
Pacira BioSciences (NASDAQ: PCRX) CMO sells 3,261 company shares - Stock Titan
Pacira BioSciences (PCRX) director sells 500 common shares in open market - Stock Titan
Pacira BioSciences unveils support hub for caregivers addressing chronic pain - Traders Union
[144] Pacira BioSciences, Inc. SE... | PCRX SEC FilingForm 144 - Stock Titan
Pacira BioSciences (NASDAQ:PCRX) Shares Down 4.7%Time to Sell? - MarketBeat
PCRX (NASDAQ: PCRX) insider sale notice lists 3 share lots - Stock Titan
Profit Review: Will Pacira BioSciences Inc benefit from seasonality2026 Big Picture & Weekly High Return Stock Opportunities - baoquankhu1.vn
Radcliffe Capital Management L.P. Takes $1.23 Million Position in Pacira BioSciences, Inc. $PCRX - MarketBeat
Pacira BioSciences advances non opioid pain therapies to transform patient care - Traders Union
Pacira BioSciences Reaffirms Commitment to Shareholder Value Creation - Sahm
Activist DOMA takes 7.3% Pacira (NASDAQ: PCRX) stake and targets CEO, board - Stock Titan
Pacira BioSciences responds to DOMA director nominations - Investing.com Australia
DOMA Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira BioSciences, Inc. - Morningstar
[DFAN14A] Pacira BioSciences, Inc. SEC Filing - Stock Titan
Activist hedge fund pushes Pacira BioSciences to sell itself - The Business Journals
Pacira Faces Board Fight As Activist Investor Criticizes CEO Pay, Missed Earnings - Benzinga
Pacira BioSciences responds to DOMA director nominations By Investing.com - Investing.com Canada
Pacira Biosciences Inc Azioni (PCRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):